Lanreotide0 vendors competing
No vendor pricing available for this peptide yet.
Research details
Lanreotide — research data
Regulatory statusFDA-approved (Somatuline)
NCAA D1Not listed
Overview
About Lanreotide
Mechanism of action
Long-acting somatostatin analog SSTR2/SSTR5 agonism suppressing GH and tumor growth
Safety profile
Injection site reactions, GI effects, cholelithiasis, bradycardia · Approved for acromegaly/NETs; GI side effects; gallstones; well-characterized
Related pages